nemonapride

structure in first source; RN given refers to compound with no isomeric designation

Also Known As:

YM 09151-2; YM 09151-M; YM-09151-2; cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide; emonapride; nemonapride, (cis)-isomer; benzamide, 5-chloro-2-methoxy-4-(methylamino)-N-(2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)-

Networked: 29 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Kaneko, S: 3 articles (08/2000 - 04/2000)
2.	Kondo, T: 3 articles (08/2000 - 04/2000)
3.	Mihara, K: 3 articles (08/2000 - 04/2000)
4.	Nagashima, U: 3 articles (08/2000 - 04/2000)
5.	Ono, S: 3 articles (08/2000 - 04/2000)
6.	Otani, K: 3 articles (08/2000 - 04/2000)
7.	Kondo, Tsuyoshi: 2 articles (04/2007 - 02/2002)
8.	Mihara, Kazuo: 2 articles (04/2007 - 02/2002)
9.	Yasui-Furukori, Norio: 2 articles (04/2007 - 02/2002)
10.	Yasui, N: 2 articles (08/2000 - 04/2000)

Related Diseases

1.	Catalepsy 09/04/1998 - "Nemonapride induced catalepsy in both cross-legged position and bar tests at low, but not at high doses. " 06/01/1997 - "After coadministration of SCH23390 and nemonapride, catalepsy was stronger than sum of the values predicted by single administration of each drug, and it was intensified synergistically. " 02/01/1987 - "Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats." 03/01/2003 - "Effective doses of terguride had no systematic effect on motor activity or muscle rigidity, whereas effective doses of nemonapride virtually eliminated motor activity and induced severe catalepsy. " 09/04/1998 - "The present data indicate that the 5-HT1A receptor agonist properties of nemonapride attenuate its ability to induce catalepsy at higher doses, and suggest further that tonic 5-HT1A receptor activation may modulate neuroleptic-induced catalepsy."
2.	Muscle Rigidity 03/01/2003 - "Effective doses of terguride had no systematic effect on motor activity or muscle rigidity, whereas effective doses of nemonapride virtually eliminated motor activity and induced severe catalepsy. "
3.	Schizophrenia (Dementia Praecox) 09/04/1998 - "This method is applicable to drug level monitoring in the plasma of schizophrenia patients treated with nemonapride and to the study of pharmacokinetics." 08/01/2000 - "These findings suggest that nemonapride has a broad therapeutic spectrum in the treatment of acute schizophrenia. " 02/01/1997 - "Nemonapride for the treatment of schizophrenia." 12/01/1996 - "Effects of nemonapride on positive and negative symptoms of schizophrenia." 03/01/1995 - "This elevation has been questioned by a fourth study that used a different method and failed to detect a biphasic component when raclopride was used to complete against the binding of 1 nM [3H]nemonapride to schizophrenia tissue. "
4.	Hyperprolactinemia 04/01/2000 - "The present study thus suggests that female patients with the A1 allele show a greater prolactin response to nemonapride, who may have a high risk for adverse effects associated with neuroleptic-induced hyperprolactinemia."
5.	Dystonia (Limb Dystonia) 02/01/1999 - "Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist." 02/01/2002 - "The most frequently observed side effects during nemonapride treatment were extrapyramidal symptoms such as akathisia (69.7%), dystonia (48.5%), hypokinesia (45.5%), tremor (39.4%) and increased salivation (36.4%). " 02/01/1999 - "Prolactin response after 1 week of treatment as an index of dopamine blockade may reflect vulnerability to the development of acute dystonia at least in male patients treated with nemonapride." 02/01/1999 - "The occurrence of acute dystonia was prospectively monitored in 39 schizophrenic patients (18 male and 21 female) treated with 9 to 27 mg/day of nemonapride, a selective dopamine antagonist, and the relationship of acute dystonia with characteristics of patients and plasma concentrations of the drug and prolactin was investigated. " 11/05/2009 - "Haloperidol, risperidone, olanzapine, nemonapride and remoxipride induced, to different extents, an increase in unusual positions (a response akin to dystonia), some crouching and static postures. "

Related Drugs and Biologics

1.	dironyl (terguride)
2.	Prolactin
3.	Dopamine (Intropin)
4.	Antipsychotic Agents (Antipsychotics)
5.	Raclopride
6.	bromperidol (Impromen)
7.	benzamide
8.	Haloperidol (Haldol)
9.	SCH 23390
10.	Sulpiride (neogama)